Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

387

Participants

Timeline

Start Date

January 23, 2019

Primary Completion Date

March 30, 2033

Study Completion Date

June 16, 2033

Conditions
Multiple Myeloma
Interventions
DRUG

Linvoseltamab

Administered per the protocol

Trial Locations (40)

1200

RECRUITING

Cliniques Universitaires Saint-Luc, Brussels

2060

RECRUITING

ZNA Psychiatrisch Ziekenhuis Stuivenberg, Antwerp

3722

RECRUITING

Yonsei University College of Medicine, Severance Hospital, Seoul

10029

ACTIVE_NOT_RECRUITING

Icahn School of Medicine at Mount Sinai, New York

10408

RECRUITING

Center for Hematologic Malignancy, Goyang-si

28006

RECRUITING

Universitary Hospital La Princesa, Madrid

28034

RECRUITING

Hospital Universitario Ramon y Cajal, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

30322

ACTIVE_NOT_RECRUITING

Emory University Hospital, Atlanta

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

33136

ACTIVE_NOT_RECRUITING

Sylvester Comprehensive Cancer Center, Miami

33612

ACTIVE_NOT_RECRUITING

Moffitt Cancer Center - McKinley Drive, Tampa

37007

RECRUITING

Hospital Clinico Universitario de Salamanca, Salamanca

40207

ACTIVE_NOT_RECRUITING

Norton Cancer Institute, Louisville

43210

ACTIVE_NOT_RECRUITING

Ohio State University James Cancer Hospital, Columbus

45147

COMPLETED

Universitatsklinikum Essen, Essen

46202

ACTIVE_NOT_RECRUITING

Indiana University_Michigan Street, Indianapolis

48201

ACTIVE_NOT_RECRUITING

Barbara Ann Karmanos Cancer Center, Detroit

55131

COMPLETED

Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz

77030

ACTIVE_NOT_RECRUITING

University of Texas MD Anderson Clinic, Houston

97239

ACTIVE_NOT_RECRUITING

Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland

98104

ACTIVE_NOT_RECRUITING

Swedish Cancer Institute, Seattle

48109-5718

ACTIVE_NOT_RECRUITING

C. S. Mott_University of Michigan, Ann Arbor

08903

ACTIVE_NOT_RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

10032-3729

ACTIVE_NOT_RECRUITING

Columbia University Medical Center, New York

6 97080

COMPLETED

Universitatsklinikum Wurzburg, Würzburg

466-8650

RECRUITING

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya

467-8602

RECRUITING

Nagoya City University Hospital, Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa-shi

371-8511

RECRUITING

Gunma University Hospital, Maebashi

309-1793

RECRUITING

Ibaraki Prefectural Central Hospital, Kasama-shi

602-8566

RECRUITING

University Hospital Kyoto Prefectural Univ of Medicine, Kyoto

350-1298

COMPLETED

Saitama Medical University International Medical Center, Hidaka

770-8539

RECRUITING

Tokushima Prefectural Central Hospital, Tokushima

150-8935

RECRUITING

Japanese Red Cross Medical Center, Shibuya-ku

160-8582

RECRUITING

Keio University Hospital, Tokyo

03080

RECRUITING

Seoul National University Cancer Hospital, Seoul

06591

RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

08041

RECRUITING

Hospital de la Santa Creu i Sant Pau, Barcelona

SM2 5PT

WITHDRAWN

Royal Marsden Hospital, Sutton

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY